Skip to main content
. 2021 May 25;31:29. doi: 10.1038/s41533-021-00241-z

Table 2.

Screening demographics and characteristics for FEV1 percent predicted subgroups (ITT population).

Predicted FEV1 at screening <50% N = 415 Predicted FEV1 at screening ≥50% N = 380
FF/UMEC/VI TIO FF/UMEC/VI TIO
n = 212 n = 203 n = 185 n = 195
Age, years, mean (SD) 65.9 (8.02) 65.2 (7.44) 66.7 (8.16) 67.0 (8.05)
Male, n (%) 149 (70) 129 (64) 123 (66) 139 (71)
BMI, kg/m2, mean (SD) 27.4 (6.4) 27.0 (5.8) 27.6 (5.7) 27.4 (4.8)
Current smoker at screening, n (%) 104 (49) 100 (49) 82 (44) 91 (47)
Lung function at screening, mean (SD)
 Post-bronchodilator FEV1, mL 1137 (314) 1097 (290) 1775 (437) 1803 (420)
 Post-bronchodilator percent predicted FEV1, % 39.2 (7.8) 38.6 (7.6) 62.1 (8.2) 62.4 (7.8)
 Post-bronchodilator FEV1/FVC ratio 0.437 (0.099) 0.445 (0.097) 0.557 (0.081) 0.561 (0.079)
 Percent reversibility to salbutamol, %a 10.9 (14.9) 9.8 (12.1) 6.3 (11.0) 7.4 (10.9)
COPD exacerbations in the previous 12 months, n (%)
Moderate COPD exacerbations
 0 117 (55) 115 (57) 27 (15) 36 (18)
 1 39 (18) 32 (16) 4 (2) 8 (4)
 ≥2 56 (26) 56 (28) 154 (83) 151 (77)
Severe COPD exacerbations
 0 168 (79) 163 (80) 148 (80) 147 (75)
 1 41 (19) 37 (18) 31 (17) 40 (21)
 ≥2 3 (1) 3 (1) 6 (3) 8 (4)
CAT score at screening, mean (SD)b 21.6 (5.58) 21.2 (5.41) 19.7 (4.68) 19.8 (4.76)
SGRQ total score at baseline, mean (SD)c 53.3 (15.39) 50.0 (15.62) 46.4 (15.55) 45.5 (14.24)

BMI body mass index, CAT COPD Assessment Test, COPD chronic obstructive pulmonary disease, FEV1 forced expiratory volume in 1 s, FF fluticasone furoate, FVC forced vital capacity, ITT intent-to-treat, SD standard deviation, SGRQ St George’s Respiratory Questionnaire, TIO tiotropium, UMEC umeclidinium, VI vilanterol.

aPercent predicted FEV1 < 50%: FF/UMEC/VI, n = 207, TIO, n = 197; percent predicted FEV1 ≥ 50%: TIO, n = 194.

bPercent predicted FEV1 < 50%: TIO, n = 202.

cPercent predicted FEV1 < 50%: FF/UMEC/VI, n = 210; percent predicted FEV1 ≥ 50%: FF/UMEC/VI, n = 184, TIO, n = 194.